18F-FDG PET-CT预测非小细胞肺癌新辅助免疫治疗主要病理缓解
该研究纳入90例接受新辅助免疫治疗的NSCLC患者,评估18F-FDG PET-CT代谢参数对主要病理缓解(MPR)的预测价值。结果显示,治疗后代谢参数及变化百分数可有效预测MPR,其中ΔSULmax%预测效能最高(AUC 0.976),优于PD-L1表达和TMB。
要点
- 新辅助免疫治疗后PET-CT代谢参数及变化百分数可预测MPR。
- ΔSULmax%预测效能最高,最佳界值-33%时灵敏度0.960、特异度0.975。
- PET-CT参数预测MPR优于PD-L1表达和TMB。
核心结论
- 新辅助免疫治疗后PET-CT代谢参数、治疗前后变化百分数及PERCIST均可预测NSCLC新辅助免疫治疗后MPR。
- ΔSULmax%预测效能最高,AUC为0.976。
- PET-CT代谢参数预测MPR的AUC优于PD-L1表达和TMB。
研究设计与样本
- 回顾性纳入2018年4月至2022年2月中国医学科学院肿瘤医院90例NSCLC患者。
- 36例接受新辅助免疫单药治疗,54例接受新辅助免疫联合其他治疗。
- 测量治疗前后原发灶SUL、MTV、TLG,依据PERCIST评估反应,病理评估MPR,检测PD-L1表达和TMB。
主要发现
- 90例中40例(44.4%)达到MPR。
- MPR组治疗后SULmax、SULpeak、SULmean、MTV、TLG均降低(均P<0.001),非MPR组无显著变化(均P>0.05)。
- 基线PET-CT代谢参数对MPR无预测价值,AUC 0.504~0.619(均P>0.05)。
- 治疗后代谢参数预测MPR的AUC为0.757~0.927(均P<0.001)。
- 代谢参数变化百分数预测MPR的AUC为0.848~0.976(均P<0.001),ΔSULmax%最高(AUC 0.976)。
关键数值与推荐
- ΔSULmax%最佳界值为-33%时,灵敏度0.960、特异度0.975、准确度0.967。
- PERCIST预测MPR的AUC为0.931(95% CI:0.881~0.981)。
- PD-L1表达预测MPR的AUC为0.686(95% CI:0.562~0.810)。
- TMB预测MPR的AUC为0.693(95% CI:0.566~0.820)。
- PET-CT参数预测MPR的AUC均优于PD-L1表达和TMB(均P<0.05)。
临床怎么用
- 新辅助免疫治疗后可用PET-CT代谢参数变化(尤其ΔSULmax%)辅助预判MPR。
- ΔSULmax%下降≥33%提示MPR可能性高,可辅助临床决策。
局限性
- 样本量有限(90例),为单中心研究。
- MPR组与非MPR组基线特征未在摘要中详述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the predictive value of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) for the major pathologic response (MPR) in non-small cell lung cancer (NSCLC) patients receiving neoadjuvant immunotherapy. Methods: A total of 36 patients who received neoadjuvant immunotherapy monotherapy and 54 patients who received neoadjuvant immunotherapy combined with other treatments at the Cancer Hospital, Chinese Academy of Medical Sciences from April 2018 to February 2022 were enrolled in this study. Radiologists measured the standardized uptake value lean body mass (SUL), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor before and after neoadjuvant immunotherapy, and evaluated the treatment response in accordance with the PET Response Criteria in Solid Tumors (PERCIST). Pathologists assessed the pathologic response of the primary tumor. The expression level of programmed cell death-ligand 1 (PD-L1) was detected by immunohistochemistry, and the tumor mutational burden (TMB) level was detected by next-generation sequencing. Receiver operating characteristic (ROC) curves were used to evaluate the performance of PET-CT metabolic parameters (baseline, post-neoadjuvant immunotherapy, and percentage change), PERCIST, PD-L1 expression, and TMB in predicting MPR. Results: Among the 90 patients, 40 (44.4%) achieved MPR after neoadjuvant immunotherapy. Compared with the baseline, the SULmax, SULpeak, SULmean, MTV and TLG in the MPR group decreased after neoadjuvant immunotherapy (all P<0.001), while no significant changes in SULmax, SULpeak, SULmean, MTV, and TLG were observed in the non-MPR group (all P>0.05). ROC curve analysis showed that baseline PET-CT metabolic parameters had no predictive value for MPR in NSCLC after neoadjuvant immunotherapy, with the AUCs ranging from 0.504 to 0.619 (all P>0.05). The AUCs of post-neoadjuvant PET-CT metabolic parameters for predicting MPR ranged from 0.757 to 0.927 (all P<0.001). The AUCs of the percentage changes in PET-CT metabolic parameters before and after neoadjuvant immunotherapy for predicting MPR ranged from 0.848 to 0.976 (all P<0.001). Among these metabolic parameters, the ΔSULmax% exhibited the highest predictive performance, with an AUC of 0.976 (P<0.001). When the optimal cutoff value of ΔSULmax% was set at -33%, the sensitivity, specificity, and accuracy were 0.960, 0.975, and 0.967, respectively. The AUC of PERCIST for predicting MPR in NSCLC after neoadjuvant immunotherapy was 0.931 (95% CI: 0.881-0.981). The AUCs of PD-L1 expression and TMB for predicting MPR in NSCLC after neoadjuvant immunotherapy were 0.686 (95% CI: 0.562-0.810) and 0.693 (95% CI: 0.566-0.820), respectively. The AUCs of PET-CT metabolic parameters (post-neoadjuvant immunotherapy, percentage changes and PERCIST) for predicting MPR were superior than those of PD-L1 expression (all P<0.05) and TMB (all P<0.05). Conclusions: PET-CT metabolic parameters post neoadjuvant immunotherapy and the percentage changes of metabolic parameters before and after neoadjuvant immunotherapy along with PERCIST can predict MPR in NSCLC receiving neoadjuvant immunotherapy. Among these parameters, the ΔSULmax% exhibited the highest predictive performance. 目的: 探究18F-氟脱氧葡萄糖(FDG)正电子发射计算机体层摄影(PET-CT)对非小细胞肺癌(NSCLC)新辅助免疫治疗后主要病理缓解(MPR)的预测价值。 方法: 纳入2018年4月至2022年2月在中国医学科学院肿瘤医院行新辅助免疫单药治疗的患者36例,行新辅助免疫联合其他治疗的患者54例。由PET-CT医师测量新辅助免疫治疗前后肿瘤原发灶瘦体质量校正的标准摄取值(SUL)、肿瘤代谢体积(MTV)和肿瘤总糖酵解值(TLG),依据实体瘤疗效PET评价标准(PERCIST)评估治疗反应。由病理科医师评估肿瘤原发灶的病理反应。采用免疫组织化学法检测程序性细胞死亡配体1(PD-L1)的表达水平,采用二代测序技术检测肿瘤突变负荷(TMB)水平。采用受试者操作特征曲线评估PET-CT代谢参数(基线、新辅助免疫治疗后和变化百分数)、依据PERCIST、PD-L1表达水平和TMB对MPR的预测效能。 结果: 90例患者中,40例(44.4%)新辅助免疫治疗后达到MPR。与基线比较,新辅助免疫治疗后MPR组SULmax、SULpeak、SULmean、MTV和TLG均降低(均P<0.001),而非MPR组SULmax、SULpeak、SULmean、MTV和TLG变化无统计学意义(均P>0.05)。ROC曲线分析显示,基线PET-CT代谢参数对NSCLC新辅助免疫治疗后MPR无预测价值,曲线下面积(AUC)为0.504~0.619(均P>0.05)。新辅助免疫治疗后PET-CT代谢参数预测NSCLC新辅助免疫治疗后MPR的AUC为0.757~0.927(均P<0.001)。新辅助免疫治疗前后PET-CT代谢参数变化百分数预测NSCLC新辅助免疫治疗后MPR的AUC为0.848~0.976(均P<0.001),其中ΔSULmax%的预测效能最高,AUC为0.976(P<0.001),最佳界值为ΔSULmax%=-33%时,灵敏度为0.960,特异度为0.975,准确度为0.967。依据PERCIST评估NSCLC新辅助免疫治疗后MPR的AUC为0.931(95% CI:0.881~0.981)。PD-L1表达和TMB对NSCLC新辅助免疫治疗后MPR的AUC分别为0.686(95% CI:0.562~0.810)和0.693(95% CI:0.566~0.820)。通过PET-CT(新辅助免疫治疗后PET-CT代谢参数、新辅助免疫治疗前后PET-CT代谢参数变化百分数、依据PERCIST)预测NSCLC新辅助免疫治疗后MPR的AUC均明显优于PD-L1表达的AUC(均P<0.05)和TMB的AUC(均P<0.05)。 结论: 新辅助免疫治疗后的PET-CT代谢参数、治疗前后代谢参数变化百分数、依据PERCIST均能预测NSCLC新辅助免疫治疗后MPR,其中ΔSULmax%的预测效能最高。.
引用
- Tao XL, Zhang Q, Li N, et al. [Predictive value of 18F-FDG PET-CT for the major pathologic response to neoadjuvant immunotherapy in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42151090. doi:10.3760/cma.j.cn112152-20250701-00307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。